N/A
Manufactured by ADMA Biologics, Inc.
73,013 FDA adverse event reports analyzed
Last updated: 2026-04-14
HUMAN IMMUNOGLOBULIN G is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ADMA Biologics, Inc.. The most commonly reported adverse reactions for HUMAN IMMUNOGLOBULIN G include OFF LABEL USE, FATIGUE, DRUG INEFFECTIVE, HEADACHE, COVID-19. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for HUMAN IMMUNOGLOBULIN G.
Out of 18,464 classified reports for HUMAN IMMUNOGLOBULIN G:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 73,013 FDA FAERS reports that mention HUMAN IMMUNOGLOBULIN G. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, FATIGUE, DRUG INEFFECTIVE, HEADACHE, COVID-19, SINUSITIS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ADMA Biologics, Inc. in connection with HUMAN IMMUNOGLOBULIN G. Always verify the specific product and NDC with your pharmacist.